30 results about "Extended Release Capsule" patented technology

The present invention is directed to an immediate release and extended release capsule or capsule fill which mitigates the abuse of abuse-susceptible active pharmaceutical ingredients by direct intravenous injection. The fill comprises a parenteral abuse resistant liquid formulation which when mixed with water and heated, results in a turbid, viscous or bubbling mixture that is not injectable with a standard insulin syringe. The abuse-susceptible active pharmaceutical ingredient is selected from the group consisting of opiates, opioids, tranquillizers, stimulants and narcotics.

The invention discloses a dexibuprofen slow-release capsule. Pellets are filled in the capsule, each pellet consists of a pellet core and four layers of materials wrapped outside the pellet core, the four layers of materials are sequentially an inner isolation layer, a first coating layer, a second coating layer and a third coating layer from inside to outside, and the pellet core, the inner isolation layer, the first coating layer, the second coating layer and the third coating layer respectively have the following compositions: the pellet core is prepared by medicine auxiliary materials, the inner isolation layer is stearic acid, the first coating layer is a coating mixture, the second coating layer comprises the coating mixture and the stearic acid, the third coating layer is the coating mixture, and the coating mixture consists of dexibuprofen and polyvidone K30. The invention also provides a production method of the dexibuprofen slow-release capsule. Compared with an ordinary capsule, the dexibuprofen slow-release capsule disclosed by the invention has the same absorption degree, but the dexibuprofen blood maximum concentration (Cmax) of the dexibuprofen slow-release capsule disclosed by the invention in human bodies is lower, the maximum time (Tmax) from the administration to the blood Cmax reaching is longer, and a good slow release effect is realized.

The invention discloses a tacrolimus slow-releasing capsule and a preparation method thereof. The tacrolimus slow-releasing capsule is a pellet capsule and has the characteristic of slowness in releasing, and is stable in dissolution degree and good in bioavailability. According to the preparation method, tacrolimus and relative auxiliary materials are prepared into coating liquid, the coating liquid is wrapped on pellet cores to form micro pellets in a coating manner, and the capsule is prepared after packing. Since the crushing, grinding or filtering of the bulk drugs or the auxiliary materials are needless in the preparation process, the bulk drugs and the auxiliary materials can be utilized to the greatest extent, as a result, the problem in the conventional preparation method of the tacrolimus slow-releasing capsule that the utilization rate of the bulk drugs and the auxiliary materials is low since composition containing the tacrolimus is required to be smashed and sieved, is solved.

The invention provides a lycium ruthenicum anthocyanin crude extract and a controlled-release microcapsule thereof. The anthocyanin crude extract has good antioxidant activity, so that the further purification for an anthocyanin monomeric compound is prevented, and meanwhile, a preparation method is simple and convenient, production materials are easily available, and the production and use costs of the lycium ruthenicum anthocyanin are reduced. The controlled-release microcapsule is an eight-hour controlled-release capsule, the drug release is uniform in speed and complete, the bioavailability of the drug is improved, and the utilization ratio of the drug is guaranteed.

Disclosed is a prescription drug for treating cardiovascular and cerebrovascular diseases which comprises the following raw materials, active constituent of safflower, active constituent of root of kudzu vine, resveratrol and its derivative, Ligustrazine and its derivative, ferulic acid and its derivative, quercetin and its derivative, rutin and its derivative or combination of any two of them, the rest are medicinal auxiliary materials. The medicine can be in the form of powder injection, liquid injection, oral liquid, capsule, slow release capsule, tablet and granule.

The present invention discloses a preparation process of slowly releasing orally taken hypoglycemic gliclazide capsule, and belongs to the field of medicinal technology field. The capsule consists of gliclazide 10-40 wt%, calcium biphosphate 40-70 wt%, HPMC4000cp 0-20 wt%, HPMC100cp 0-20 wt%, EC100cp 0-9.3 wt%, magnesium stearate 0-2 wt% and talcum powder 0-2 wt%. The preparation process includes 60-100 mesh sieving the first mentioned five medicine materials, mixing, adding 50-75 % concentration alcohol as wetting agent and stirring to making soft material, 14-20 mesh sieve pelletizing, drying at 50-60 deg.c of 1-2 hr, 14-20 mesh sieve finishing, adding magnesium stearate and talcum powder, and capsulizing. The capsule is used in treating non-insulin dependent diabetes (type-II), is especially suitable for adult diabetes, diabetes accompanied by obesity or blood vessel pathologic change, and has the features of being safe and long in effect.

The slow released mexiletine hydrochloride preparation consists of mexiletine hydrochloride as active component in 20-70 wt%, slow releasing material in 10-60 wt%, and medicinal supplementary material. It is prepared into slow released tablet or capsule through sieving the materials, mixing, pelletizing, and tabletting or encapsulating. It has both fast releasing and slow releasing feature, fast acting, high bioavailability, long acting period, taking safety and other advantages.

The invention relates to a venlafaxine hydrochloride slow-release capsule and a preparation method thereof. A drug-containing core of the slow-release capsule comprises venlafaxine hydrochloride, microcrystalline cellulose, gas phase silica, Tween-80, and hydroxypropyl methylcellulose; a slow-release coating comprises polyacrylic resin, talcum powder, polyethylene glycol and lauryl sodium sulfate. The invention realizes a pure water system for the capsule production by the addition of gas phase silica to change material flowing, and the selection of slow-release coating. The venlafaxine hydrochloride slow-release capsule prepared by the system is stable in drug release, has effective continuous release time of 24 hours, and is taken only once a day. The method is simple in process, mild in condition, free of any organic solvent, low in equipment requirements, and suitable for industrial production.

The invention discloses a compound sildennafil dapoxetine slow-release capsule and a preparation method thereof. Each capsule of the preparation contains immediate-release particles and slow-release particles. The immediate-release particles contain an active substance sildennafil or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient or auxiliary materials; the slow-release particles contain an active substance dapoxetine or the pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient or auxiliary materials. The preparation is prepared by the following steps: preparation of excipient immediate-release particles; preparation of dapoxetine slow-release particles; preparation of the compound sildennafil dapoxetine slow-release capsule. In the compound preparation, sildennafil is used as an immediate-release component, drug effects are rapidly performed, sexual desire of patients is satisfied in a short time, dapoxetine is used as a slow-release component for time-delay release, the effects are lasting for patients, and the capsule is suitable for treating erectile dysfunction and premature ejaculation of male.

The invention relates to a hepatitis viruse-resisting Chinese medicinal composition and process for preparation, which is prepared from Chinese herbal extract including blattbulume, flavescent sophora root, licorice root as well as ginseng leaves saponins and medicinal auxiliary materials. The preparation can be made into various oral forms including tablet, capsule, granule, soft capsule, drop pill, oral liquid, slow release tablet and slow release capsule.

The invention provides a low cost preparation method for a negative hydrogen ion antioxidant and a zinc-boron supplement, and relates to research on human anti-oxidation and trace element supplement health care products in the field of chemical industry pharmacy. In the prior art, the negative hydrogen ion supplement is mainly the hydrogen-containing sintered coral calcium developed and researched by Japanese, adopts coral in sea as the main raw material, and has disadvantages of scarce resource, limitation by environmental protection, and incapable random exploitation, such that the problems of limited production, high cost and difficult application for the majority of ordinary people exist. Based on the problems in the prior art, the invention provides the low cost preparation method for the negative hydrogen ion antioxidant and the zinc-boron supplement, wherein the method is characterized in that the low-price and easy-availability pharmaceutical pure chemical industry products zinc borohydride and active carbon powder are adopted as the raw materials, and the modern matured pharmaceutical process is adopted to finally prepare into the edible slow-release capsules or enteric tablets, such that the efficient antioxidant health care product negative hydrogen ions and zinc-boron supplement with characteristics of low price, easy popularization and generalization, and low economic burden is obtained so as to improve the health level of the people and provide benefits for the whole mankind.

The invention provides acetylsalicylic acid slow release capsules and a preparation method thereof, and belongs to the technical field of medicines. The contents of the acetylsalicylic acid slow release capsules comprise acetylsalicylic acid slow release granules which are sequentially acetylsalicylic acid crystals, an isolating layer and a slow release layer from the inner part to the outer part,acetylsalicylic acid slow release granules which are sequentially acetylsalicylic acid crystals and the slow release layer from the inner part to the outer part, and a mixture thereof. A preparationmethod of the granules is realized through a fluidization bed coating technique and comprises the steps of coating the acetylsalicylic acid crystals with an isolating layer; preparing the granules forthe coating of the slow release layer for the acetylsalicylic acid crystals coated with the isolation coating; or directly preparing the slow release granules for the coating the slow release layer for the acetylsalicylic acid crystals. The release behavior lies in that the medicine release dosage within 30min is small than 10%, the drug release dosage is 45%-55% and the drug release dosage within 24h is 70% or above. The obtained acetylsalicylic acid slow release capsules have high repeatability, good stability and obvious slow release effects. The acetylsalicylic acid slow release capsuleshave the characteristics of being stable and durable in blood drug level, low in side effects, high in compliance and the like.

An improved extended release capsule of cyclobenzaprine, and in particular, cyclobenzaprine hydrochloride, is provided. The improved capsule, comprising one or more matrix-type tablets providing extended release of the cyclobenzaprine, provides a dosage form that is bioequivalent to the currently marketed AMRIX® capsules while providing a simplified manufacturing process. Also provided is a method for the preparation of the improved extended release capsule of cyclobenzaprine.

An improved extended release capsule of cyclobenzaprine, and in particular, cyclobenzaprine hydrochloride, is provided. The improved capsule, comprising one or more matrix-type tablets providing extended release of the cyclobenzaprine, provides a dosage form that is bioequivalent to the currently marketed AMRIX® capsules while providing a simplified manufacturing process. Also provided is a method for the preparation of the improved extended release capsule of cyclobenzaprine.

An improved extended release capsule of cyclobenzaprine, and in particular, cyclobenzaprine hydrochloride, is provided. The improved capsule, comprising one or more matrix-type tablets providing extended release of the cyclobenzaprine, provides a dosage form that is bioequivalent to the currently marketed AMRIX® capsules while providing a simplified manufacturing process. Also provided is a method for the preparation of the improved extended release capsule of cyclobenzaprine.

The present invention provides an extended-release capsule dosage form of metoprolol succinate in the form of coated discrete units and processes for their preparation.

This disclosure provides an extended-release capsule dosage form of metoprolol succinate in the form of coated discrete units, wherein said capsule dosage form is bioequivalent to the marketed ToprolXL® tablet. The extended-release capsule dosage form comprising coated discrete units can be sprinkled onto food to ease administration to patients who have difficulty swallowing tablets or capsules.

This disclosure provides an extended-release capsule dosage form of metoprolol succinate in the form of coated discrete units, wherein said capsule dosage form is bioequivalent to the marketed Toprol-XL® tablet. The extended-release capsule dosage form comprising coated discrete units can be sprinkled onto food to ease administration to patients who have difficulty swallowing tablets or capsules.

The present invention relates to an extended release capsules comprising multiple units of Capecitabine, wherein the dissolution of Capecitabine from the said composition is extended up to 12 hours. Further the present invention discloses process for the preparation of the said composition.

The present invention is one kind of slow released capsule with slow released indapamide microcapsule as main component and homogeneous medicine release. The slow released microcapsule includes medicine microcapsule with indapamide as active component and slow releasing coating layer around the medicine microcapsule. The supplementary material includes supplementary material to constitute the medicine microcapsule together with indapamide and the slow releasing material. In the slow released microcapsule, the weight ratio of indapamide, the supplementary material and the slow releasing material is 0.5-3.0 to 1-10 to 165-400. The slow released microcapsule is prepared through a coating process. The slow released preparation of the present invention has prolonged in vivo residence time of the medicine, controlled medicine release, lowered toxic side effect and raised curative effect.

The invention discloses a traditional-Chinese-medicine slow-release capsule for improving the immunity and a preparation method thereof. The traditional-Chinese-medicine slow-release capsule is prepared from the following raw materials in parts by weight: 12-16 parts of suncured radix ginseng, 13-18 parts of epimedium herb, 28-32 parts of processed radix aconiti lateralis, 12-18 parts of dried ginger, 13-18 parts of radix morindae officinalis, 12-17 parts of cassia twig, 13-18 parts of rhizoma pinelliae preparatum, 12-18 parts of rhizoma acori graminei, 12-16 parts of radix notoginseng and 4-8parts of radix et rhizoma rhei. The preparation method comprises the following steps of: (1) alcohol extraction; (2) water extraction; (3) spraying and drying; (4) preparation of coating liquid; (5)preparation of coating particles; (6) capsulation. The traditional-Chinese-medicine slow-release capsule has the beneficial effects that the functions of cellular immunity and humoral immunity of an organism can be enhanced, the physiological functions of lymphocytes, mononuclear macrophages and hematopoietic stem cells can be promoted, simultaneously the liver, the kidney, the heart, the spleen and the lung of a human body can be comprehensively conditioned, prevention is carried out from the inner part of the body and the immunity capability of the organism is improved; the traditional-Chinese-medicine slow-release capsule is wide in application range, has no toxic and side effects for the human body, also has a slow-release effect after coating treatment and has lasting pharmaceutical effect.